Edwards Lifesciences Co. (NYSE:EW) Position Increased by Wedbush Securities Inc.

Wedbush Securities Inc. lifted its position in Edwards Lifesciences Co. (NYSE:EW) by 1.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,889 shares of the medical research company’s stock after acquiring an additional 285 shares during the period. Wedbush Securities Inc.’s holdings in Edwards Lifesciences were worth $1,745,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Crewe Advisors LLC purchased a new position in Edwards Lifesciences during the 1st quarter worth approximately $28,000. First Community Trust NA purchased a new position in shares of Edwards Lifesciences during the second quarter valued at $29,000. Riverview Trust Co purchased a new stake in Edwards Lifesciences in the 1st quarter worth about $34,000. DSM Capital Partners LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth about $28,000. Finally, Webster Bank N. A. acquired a new stake in Edwards Lifesciences during the 2nd quarter worth about $39,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total transaction of $466,450.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total transaction of $466,450.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The disclosure for this sale can be found here. Insiders sold a total of 16,250 shares of company stock worth $1,321,988 in the last ninety days. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Trading Down 1.6 %

Shares of NYSE:EW opened at $65.71 on Tuesday. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The company has a market cap of $39.58 billion, a P/E ratio of 28.32, a P/E/G ratio of 2.79 and a beta of 1.13. The stock’s 50-day moving average is $74.26 and its 200-day moving average is $83.98.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. During the same period in the previous year, the business posted $0.66 EPS. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. Equities research analysts predict that Edwards Lifesciences Co. will post 2.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

EW has been the subject of a number of research analyst reports. Baird R W lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Daiwa Capital Markets upgraded shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a report on Wednesday, July 31st. Canaccord Genuity Group cut their price objective on Edwards Lifesciences from $85.00 to $77.00 and set a “hold” rating for the company in a report on Thursday, July 25th. Wolfe Research upgraded Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday, July 29th. Finally, Robert W. Baird lowered Edwards Lifesciences from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $102.00 to $70.00 in a research report on Thursday, July 25th. Fourteen equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $81.10.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.